You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for RG1662

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug RG1662?

RG1662 is an investigational drug.

There have been 9 clinical trials for RG1662. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Down Syndrome, Syndrome, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

There are nine US patents protecting this investigational drug and one hundred and nineteen international patents.

Recent Clinical Trials for RG1662
A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of AgeHoffmann-La RochePhase 2
A Brain Imaging Study to Assess GABAA Receptor Alpha5 Subunit Occupancy Following a Single Dose of RO5186582 in Japanese Healthy Volunteers.Hoffmann-La RochePhase 1
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy SubjectsHoffmann-La RochePhase 1

See all RG1662 clinical trials

Clinical Trial Summary for RG1662

Top disease conditions for RG1662
Top clinical trial sponsors for RG1662

See all RG1662 clinical trials

US Patents for RG1662

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RG1662   Start Trial Isoxazolo-pyridine derivatives Hoffmann-La Roche Inc (Nutley, NJ)   Start Trial
RG1662   Start Trial Process for the preparation of isoxazolyl-methoxy nicotinic acids Hoffman-La Roche Inc. (Nutley, NJ)   Start Trial
RG1662   Start Trial Solid forms Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
RG1662   Start Trial Use of selective GABA A .alpha.5 negative allosteric modulators for the treatment of central nervous system conditions Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
RG1662   Start Trial Isoxazolo-pyridine derivatives Roche Palo Alto LLC (So. San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RG1662

Drugname Country Document Number Estimated Expiration Related US Patent
RG1662 Argentina 069523 2027-12-04   Start Trial
RG1662 Australia 2008333326 2027-12-04   Start Trial
RG1662 Brazil PI0820112 2027-12-04   Start Trial
RG1662 Canada 2707648 2027-12-04   Start Trial
RG1662 Chile 2008003591 2027-12-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.